Research
Hormonal
GLP-1RAs activate neurons in the paraventricular nucleus (PVH) and ventromedial hypothalamus (VMH) to suppress food intake and increase energy expenditure or thermogenesis.
GLP-1 medications also target other brain regions (PVH and VMH) to suppress food intake and increase energy expenditure. This helps explain why these medications can lead to weight loss even without significant changes in diet or exercise.
ModerateSupportsMEDIUM confidence
Direct injection of GLP-1, exendin-4, or liraglutide to the PVH indeed suppressed food intake... Liraglutide injection into the VMH of mice induced weight loss and increased thermogenetic activity, as evidenced by elevated uncoupling protein 1 expression in both BAT and white adipose tissue.
Why this rating
Supported by animal studies, but human relevance and consistency are less clear.
Source
Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
Joon Seok Park et al. · Diabetes & Metabolism Journal · 2025
DOI 10.4093/dmj.2025.0106
narrative_reviewCited 21×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) induce pre-ingestive, cognitive satiation by activating dorsomedial hypothalamus (DMH) GLP-1R neurons, which inhibit arcuate nucleus AgRP neurons to terminate meals before ingestion begins.Good
- GLP-1RAs reduce food intake and body weight by activating POMC neurons and inhibiting NPY/AgRP neurons in the arcuate nucleus (ARC) of the hypothalamus.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →